Literature DB >> 22037251

Host-derived MCP-1 and MIP-1α regulate protective anti-tumor immunity to localized and metastatic B16 melanoma.

Yuko Nakasone1, Manabu Fujimoto, Takashi Matsushita, Yasuhito Hamaguchi, Doanh Le Huu, Mizuki Yanaba, Shinichi Sato, Kazuhiko Takehara, Minoru Hasegawa.   

Abstract

Leukocytic infiltration into malignant melanoma lesions is tightly regulated by chemokines. To assess the role of the CC chemokines monocyte chemotactic protein-1 (MCP-1/chemokine ligand 2) and macrophage inflammatory protein-1α (MIP-1α/chemokine ligand 3) in this process, s.c. primary and metastatic B16 F10 melanoma tumor growth levels were examined in mice lacking MCP-1 or MIP-1α. Primary s.c. B16 F10 melanoma growth was augmented by loss of MCP-1 or MIP-1α. Similarly, lung metastasis was enhanced by the deficiency of MCP-1 or MIP-1α. Enhanced tumor outgrowth was associated with decreased percentages of infiltrating CD4(+) T cells, CD8(+) T cells, and natural killer cells. In the absence of MCP-1 or MIP-1α, melanoma outgrowth was correlated with reduced local expression of interferon-γ, IL-6, tumor necrosis factor-α, and transforming growth factor-β. Among these cytokines, reduced expression levels of interferon-γ and tumor necrosis factor-α on leukocytes from the spleen were associated with the development of lung metastasis in chemokine-deficient mice. The local s.c. administration of these four cytokines significantly augmented another chemokine's expression and suppressed primary melanoma growth in mice deficient for MCP-1 or MIP-1α. The s.c. injection of MCP-1 or MIP-1α significantly inhibited the primary tumor growth in wild-type mice. These results indicate that host-derived MCP-1 and MIP-1α regulate protective anti-tumor immunity to B16 F10 melanoma by promoting lymphocyte infiltration into the tumor and subsequent cytokine production.
Copyright © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22037251     DOI: 10.1016/j.ajpath.2011.09.005

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  30 in total

1.  Serum CCL2 and CCL3 as potential biomarkers for the diagnosis of oral squamous cell carcinoma.

Authors:  Liang Ding; Bing Li; Ying Zhao; Yi-Fu Fu; Er-Ling Hu; Qin-Gang Hu; Yan-Hong Ni; Ya-Yi Hou
Journal:  Tumour Biol       Date:  2014-07-25

Review 2.  Basophils as a potential therapeutic target in cancer.

Authors:  Jicheng Zhang; Hanlin Yin; Qiangda Chen; Guochao Zhao; Wenhui Lou; Wenchuan Wu; Ning Pu
Journal:  J Zhejiang Univ Sci B       Date:  2021-12-15       Impact factor: 3.066

3.  Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.

Authors:  Deborah A Knight; Shin Foong Ngiow; Ming Li; Tiffany Parmenter; Stephen Mok; Ashley Cass; Nicole M Haynes; Kathryn Kinross; Hideo Yagita; Richard C Koya; Thomas G Graeber; Antoni Ribas; Grant A McArthur; Mark J Smyth
Journal:  J Clin Invest       Date:  2013-02-01       Impact factor: 14.808

4.  The activation of HMGB1 as a progression factor on inflammation response in normal human bronchial epithelial cells through RAGE/JNK/NF-κB pathway.

Authors:  Xiaojin Wu; Yanyan Mi; Hui Yang; Ankang Hu; Qingguo Zhang; Chunli Shang
Journal:  Mol Cell Biochem       Date:  2013-05-26       Impact factor: 3.396

5.  Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.

Authors:  Keisuke Watanabe; Yanping Luo; Tong Da; Sonia Guedan; Marco Ruella; John Scholler; Brian Keith; Regina M Young; Boris Engels; Suvi Sorsa; Mikko Siurala; Riikka Havunen; Siri Tähtinen; Akseli Hemminki; Carl H June
Journal:  JCI Insight       Date:  2018-04-05

6.  OX40 agonist combined with irreversible electroporation synergistically eradicates established tumors and drives systemic antitumor immune response in a syngeneic pancreatic cancer model.

Authors:  Qi-Wei Zhang; Xiao-Xia Guo; Yu Zhou; Qing-Bing Wang; Qin Liu; Zhi-Yuan Wu; Xiao-Yi Ding
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

7.  Microfluidic model with air-walls reveals fibroblasts and keratinocytes modulate melanoma cell phenotype, migration, and metabolism.

Authors:  Jose M Ayuso; Shreyans Sadangi; Marcos Lares; Shujah Rehman; Mouhita Humayun; Kathryn M Denecke; Melissa C Skala; David J Beebe; Vijayasaradhi Setaluri
Journal:  Lab Chip       Date:  2021-02-03       Impact factor: 6.799

8.  Thrombin-PAR1 signaling in pancreatic cancer promotes an immunosuppressive microenvironment.

Authors:  Patrick G Schweickert; Yi Yang; Emily E White; Gregory M Cresswell; Bennett D Elzey; Timothy L Ratliff; Paritha Arumugam; Silvio Antoniak; Nigel Mackman; Matthew J Flick; Stephen F Konieczny
Journal:  J Thromb Haemost       Date:  2020-10-25       Impact factor: 5.824

9.  Cancer immunosurveillance: role of patrolling monocytes.

Authors:  Luca Cassetta; Jeffrey W Pollard
Journal:  Cell Res       Date:  2015-12-04       Impact factor: 25.617

10.  Immunotherapy of human papilloma virus induced disease.

Authors:  Sjoerd H van der Burg
Journal:  Open Virol J       Date:  2012-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.